Outcome assessments in rheumatoid arthritis

Katarzyna Gilek-Seibert, Kara Prescott, Salahuddin Kazi

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Increasing evidence suggests low disease activity or remission is achievable in rheumatoid arthritis (RA). Using a treat to target strategy (T2T) has been shown to achieve these targets of remission or low disease activity in RA. In order to successfully treat to target, rheumatologists need reliable measures of disease activity to switch and/or escalate therapy to achieve or maintain therapeutic targets. Multiple diseaseactivity measures have been developed for both research and clinical practice. For clinical practice, the American College of Rheumatology (ACR) has recommended the PAS, PAS II, RAPID 3, CDAI, DAS 28, and SDAI for measuring disease activity in rheumatoid arthritis. Each of these measures has strengths and limitations, but they all accurately reflect disease activity, discriminate well between disease states, and are feasible to perform in the clinical setting. Implementation in the clinical setting can be optimized through leveraging technology and systems redesign. Tools such as web-based and smartphone applications have been developed to increase the ease with which these measures can be deployed. Diseaseactivity measurement in rheumatoid arthritis is included in the rheumatoid arthritis quality measures group in the Centers for Medicare and Medicaid Services' incentive-based Physician Quality Reporting System.

Original languageEnglish (US)
Article number370
JournalCurrent Rheumatology Reports
Issue number11
StatePublished - Nov 1 2013


  • ACR
  • American College of Rheumatology
  • CDAI
  • DAS
  • DAS 28
  • Disease activity measures
  • European league against Rheumatism
  • Guidelines
  • Medical apps
  • Outcomes
  • PAS
  • PAS II
  • Patient-reported outcomes
  • RAPID3
  • Rheumatoid arthritis (RA)
  • SDAI
  • Treat to target strategy

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Outcome assessments in rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this